Overview

A Study To Investigate The Effect Of 28 Days Of Dosing With GW856553 On Patients With Rheumatoid Arthritis

Status:
Completed

Trial end date:
2008-01-01

Target enrollment:

Participant gender:

Summary

This study is designed to look at the safety, tolerability and effectiveness of 28 days of dosing of GW856553 in rheumatoid arthritis patients.

Phase:

Phase 2

Details

Lead Sponsor:

GlaxoSmithKline